- Home
- KAVL vs SNOA Comparison
KAVL vs SNOA Comparison
Compare KAVL & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- SNOA
- Stock Information
- Founded
- KAVL 1998
- SNOA 1999
- Country
- KAVL United States
- SNOA United States
- Employees
- KAVL N/A
- SNOA N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- SNOA Health Care
- Exchange
- KAVL Nasdaq
- SNOA Nasdaq
- Market Cap
- KAVL 7.9M
- SNOA 6.4M
- IPO Year
- KAVL N/A
- SNOA 2007
- Fundamental
- Price
- KAVL $0.49
- SNOA $2.90
- Analyst Decision
- KAVL
- SNOA
- Analyst Count
- KAVL 0
- SNOA 0
- Target Price
- KAVL N/A
- SNOA N/A
- AVG Volume (30 Days)
- KAVL 26.0K
- SNOA 32.7K
- Earning Date
- KAVL 06-10-2025
- SNOA 06-17-2025
- Dividend Yield
- KAVL N/A
- SNOA N/A
- EPS Growth
- KAVL N/A
- SNOA N/A
- EPS
- KAVL N/A
- SNOA N/A
- Revenue
- KAVL $1,698,426.00
- SNOA $14,288,000.00
- Revenue This Year
- KAVL N/A
- SNOA $38.54
- Revenue Next Year
- KAVL N/A
- SNOA N/A
- P/E Ratio
- KAVL N/A
- SNOA N/A
- Revenue Growth
- KAVL N/A
- SNOA 12.20
- 52 Week Low
- KAVL $0.46
- SNOA $1.75
- 52 Week High
- KAVL $1.95
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- KAVL 36.05
- SNOA 38.85
- Support Level
- KAVL $0.52
- SNOA $2.81
- Resistance Level
- KAVL $0.56
- SNOA $3.45
- Average True Range (ATR)
- KAVL 0.03
- SNOA 0.13
- MACD
- KAVL -0.00
- SNOA -0.05
- Stochastic Oscillator
- KAVL 0.57
- SNOA 10.77
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.